ReviewTurkish thoracic journal2020
Lung Cancer Management in COVID-19 Pandemic.
Review in Turkish thoracic journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.Critical reviews in oncology/hematology · 2021Pooled it
- Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis.Oncology letters · 2023Article
- Impact of COVID-19 Pandemic on Advanced Non-small Cell Lung Cancer Treatment at a Japanese Hospital.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In studies published in China, lung cancer patients were identified as the greatest risk group during the COVID-19 pandemic due to their diseases and immunosuppressive treatments. Poor prognosis is anticipated if COVID-19 pneumonia is detected in lung cancer patients. Oncology associations and specialists from countries such as China and Italy have published suggestions that allow patients to experience the pandemic with minimal harm. It is recommended that patients stay in their homes and not visit the hospital. This may mean postponing treatments, switching to oral form of treatments that must continue, and extending the intervals between IV treatments or reducing the number of cycles. When surgery is required, neoadjuvant chemotherapies are preferred. It is difficult to differentiate the symptoms or radiological images of the lung cancer patient with COVID 19 pneumonia vs cancer progression or treatment-related complications. Therefore, careful examination is key. In this article, we have compiled recommendations for the management of lung cancer during the COVID 19 pandemic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.